CTOs on the Move

Ideaya Biosciences

www.ideayabio.com

 
IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA`s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and La Jolla, California.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ideayabio.com
  • 7000 Shoreline Court Suite 350
    South San Francisco, CA USA 94080
  • Phone: 650.443.6209

Executives

Name Title Contact Details
Solomon Wang
Director, IT Profile

Funding

Ideaya Biosciences raised $94M on 03/15/2018
Ideaya Biosciences raised $86.1M on 07/07/2021

Similar Companies

Sensorion

Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).

Evidence CPR

EVIDENCE takes care of continuous education of investigators in clinical trials and takes every effort to help them keep a high level of practical knowledge of GCP (Good Clinical Practice) and other aspects of clinical trails. EVIDENCE offers GCP courses

Draper

As a nonprofit engineering innovation company, Draper serves our nation`s interests and security needs; advances technologies at the intersection of government, academia, and industry; cultivates the next generation of innovators; and solves the most complex challenges. Multidisciplinary teams drawn from a broad and deep talent pool of 1,200 engineers and scientists collaborate to develop first-of-a-kind solutions. Our unbiased approach enables us to focus on our customers` needs and to deliver new capabilities to them.

Brightseed

Brightseed enables a healthier future by illuminating and activating the connections between people and plants. Despite centuries of wisdom proving the critical roles plants play in supporting our health, the majority of active compounds in the plant kingdom remain unexplored. Our artificial intelligence, Forager®, reveals powerful compounds hidden in nature and our team scientifically validates their impact.

Singular Genomics

Singular Genomics is pushing sequencing further to bring fast, powerful and flexible tools for research and medicine. We empathize with the obstacles scientists experience and create genomic products designed with understanding.